Related Experiment Video
Updated: Jul 3, 2026

Facile Preparation of 4-Substituted Quinazoline Derivatives
Published on: February 15, 2016
Fleroxacin: the newly introduced once-daily quinoline
1Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA.
Abstract:
Fleroxacin is a new oral and intravenous trifluoroquinolone with a half-life of 10-12 h. This new quinolone has excellent bioavailability, good tissue penetration, low protein binding and a low rate of metabolism. Serum concentrations following oral and intravenous administration are identical, allowing the clinician to change comfortably from intravenous to oral therapy. Fleroxacin exhibits a broad spectrum af antibacterial activity against aerobic Gram-negative bacteria, and also against staphylococci. Comparative clinical studies have demonstrated efficacy and safety of fleroxacin as treatment for infectious of the urinary and respiratory tract, sexually transmitted diseases, infections of the skin and soft tissue and gastrointestinal tract, in a large number of adult patients of various ages. These data suggest that fleroxacin will be an effective once-daily agent in the treatment of a variety of infections caused by bacteria susceptible to this new long-acting quinolone.
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
Antiprotozoal Agents
Oxidation of Phenols to Quinones
o-hydroxy phenols are oxidized to o-quinones and p-hydroxy phenols to p-quinones. Such redox reactions involve the transfer of two electrons and two protons. The reversible redox property is crucial in...
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
Electrophilic Aromatic Substitution: Fluorination and Iodination of Benzene
Antibiotic Selection

